261 related articles for article (PubMed ID: 22526021)
1. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.
Hart MP; Brettschneider J; Lee VM; Trojanowski JQ; Gitler AD
Acta Neuropathol; 2012 Aug; 124(2):221-30. PubMed ID: 22526021
[TBL] [Abstract][Full Text] [Related]
2. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.
Hart MP; Gitler AD
J Neurosci; 2012 Jul; 32(27):9133-42. PubMed ID: 22764223
[TBL] [Abstract][Full Text] [Related]
3. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions.
Highley JR; Lorente Pons A; Cooper-Knock J; Wharton SB; Ince PG; Shaw PJ; Wood J; Kirby J
Neuropathol Appl Neurobiol; 2016 Jun; 42(4):377-89. PubMed ID: 26095883
[TBL] [Abstract][Full Text] [Related]
4. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.
Lee T; Li YR; Ingre C; Weber M; Grehl T; Gredal O; de Carvalho M; Meyer T; Tysnes OB; Auburger G; Gispert S; Bonini NM; Andersen PM; Gitler AD
Hum Mol Genet; 2011 May; 20(9):1697-700. PubMed ID: 21292779
[TBL] [Abstract][Full Text] [Related]
5. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
[TBL] [Abstract][Full Text] [Related]
6. Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72.
McGurk L; Lee VM; Trojanowksi JQ; Van Deerlin VM; Lee EB; Bonini NM
J Neuropathol Exp Neurol; 2014 Sep; 73(9):837-45. PubMed ID: 25111021
[TBL] [Abstract][Full Text] [Related]
7. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?
van den Heuvel DM; Harschnitz O; van den Berg LH; Pasterkamp RJ
Trends Mol Med; 2014 Jan; 20(1):25-35. PubMed ID: 24140266
[TBL] [Abstract][Full Text] [Related]
8. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.
Conforti FL; Spataro R; Sproviero W; Mazzei R; Cavalcanti F; Condino F; Simone IL; Logroscino G; Patitucci A; Magariello A; Muglia M; Rodolico C; Valentino P; Bono F; Colletti T; Monsurrò MR; Gambardella A; La Bella V
Neurology; 2012 Dec; 79(24):2315-20. PubMed ID: 23197749
[TBL] [Abstract][Full Text] [Related]
9. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.
Elden AC; Kim HJ; Hart MP; Chen-Plotkin AS; Johnson BS; Fang X; Armakola M; Geser F; Greene R; Lu MM; Padmanabhan A; Clay-Falcone D; McCluskey L; Elman L; Juhr D; Gruber PJ; Rüb U; Auburger G; Trojanowski JQ; Lee VM; Van Deerlin VM; Bonini NM; Gitler AD
Nature; 2010 Aug; 466(7310):1069-75. PubMed ID: 20740007
[TBL] [Abstract][Full Text] [Related]
10. Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS.
Bonini NM; Gitler AD
J Mol Neurosci; 2011 Nov; 45(3):676-83. PubMed ID: 21660502
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis.
Lee T; Li YR; Chesi A; Hart MP; Ramos D; Jethava N; Hosangadi D; Epstein J; Hodges B; Bonini NM; Gitler AD
Neurology; 2011 Jun; 76(24):2062-5. PubMed ID: 21562248
[TBL] [Abstract][Full Text] [Related]
12. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.
Yu Z; Zhu Y; Chen-Plotkin AS; Clay-Falcone D; McCluskey L; Elman L; Kalb RG; Trojanowski JQ; Lee VM; Van Deerlin VM; Gitler AD; Bonini NM
PLoS One; 2011 Mar; 6(3):e17951. PubMed ID: 21479228
[TBL] [Abstract][Full Text] [Related]
13. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion.
Brettschneider J; Van Deerlin VM; Robinson JL; Kwong L; Lee EB; Ali YO; Safren N; Monteiro MJ; Toledo JB; Elman L; McCluskey L; Irwin DJ; Grossman M; Molina-Porcel L; Lee VM; Trojanowski JQ
Acta Neuropathol; 2012 Jun; 123(6):825-39. PubMed ID: 22426854
[TBL] [Abstract][Full Text] [Related]
14. Evidence that TDP-43 is not the major ubiquitinated target within the pathological inclusions of amyotrophic lateral sclerosis.
Sanelli T; Xiao S; Horne P; Bilbao J; Zinman L; Robertson J
J Neuropathol Exp Neurol; 2007 Dec; 66(12):1147-53. PubMed ID: 18090923
[TBL] [Abstract][Full Text] [Related]
15. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
16. The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.
Gispert S; Kurz A; Waibel S; Bauer P; Liepelt I; Geisen C; Gitler AD; Becker T; Weber M; Berg D; Andersen PM; Krüger R; Riess O; Ludolph AC; Auburger G
Neurobiol Dis; 2012 Jan; 45(1):356-61. PubMed ID: 21889984
[TBL] [Abstract][Full Text] [Related]
17. Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral sclerosis.
Figley MD; Thomas A; Gitler AD
Neurobiol Aging; 2014 Apr; 35(4):936.e1-4. PubMed ID: 24269018
[TBL] [Abstract][Full Text] [Related]
18. TDP-43 pathology in polyglutamine diseases: with reference to amyotrphic lateral sclerosis.
Toyoshima Y; Takahashi H
Neuropathology; 2014 Feb; 34(1):77-82. PubMed ID: 23889603
[TBL] [Abstract][Full Text] [Related]
19. FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansion.
Bäumer D; East SZ; Tseu B; Zeman A; Hilton D; Talbot K; Ansorge O
Acta Neuropathol; 2014 Oct; 128(4):597-604. PubMed ID: 24718895
[TBL] [Abstract][Full Text] [Related]
20. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia.
Mori F; Tanji K; Zhang HX; Nishihira Y; Tan CF; Takahashi H; Wakabayashi K
Acta Neuropathol; 2008 Aug; 116(2):193-203. PubMed ID: 18560845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
